VCP
ICPT

Verus Capital Partners’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Verus Capital Partners’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4K Sell
60
-70
-54% -$6.29K ﹤0.01% 1245
2019
Q4 		$16K Buy
+130
New +$11.6K 0.01% 985

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Verus Capital Partners's ICPT Position: Q1 2020 in Review

Verus Capital Partners reduced its Intercept Pharmaceuticals, Inc. (ICPT) stake by 54% in Q1 2020, selling an estimated $6.29K and leaving 60 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

Verus Capital Partners first reported a position in ICPT in Q4 2019 and has held it in 2 quarters since. The position peaked at $16K in Q4 2019. 188 funds tracked by Wall St. Rank hold ICPT as of Q1 2020.

  • Verus Capital Partners held 60 shares of Intercept Pharmaceuticals, Inc. worth $4K as of Q1 2020.
  • Verus Capital Partners sold 70 Intercept Pharmaceuticals, Inc. shares in Q1 2020, an estimated $6.29K.
  • Intercept Pharmaceuticals, Inc. made up ﹤0.01% of Verus Capital Partners's portfolio in Q1 2020, its #1245 holding.
  • Verus Capital Partners first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2019 and has held it in 2 quarters since.
  • Verus Capital Partners's Intercept Pharmaceuticals, Inc. position peaked at $16K in Q4 2019.
  • 188 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.